MLTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MoonLake Immunotherapeutics (MLTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including promising clinical trial results, multiple analyst upgrades, and a clear regulatory path for its key drug candidate. Despite minor pre-market price fluctuations, the long-term growth potential outweighs short-term volatility.
The MACD is positive at 0.13, indicating bullish momentum, though it is contracting. RSI is neutral at 52.038, suggesting no overbought or oversold conditions. Moving averages are converging, which signals consolidation. Key support is at 15.877, and resistance is at 19.101. The stock is currently trading near the pivot level of 17.489, indicating a balanced price point.
Positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis and hidradenitis suppurativa.
Multiple analyst upgrades with price targets as high as $45, highlighting the drug's blockbuster potential.
Clear regulatory path with no additional clinical trials required for FDA approval.
Long-term growth potential with a catalyst-rich 2026 setup.
Minor pre-market price drop of -0.17%.
Broader market uncertainty due to global tariff increases announced by President Trump.
In Q4 2025, the company's net income improved by 36.89% YoY, and EPS increased by 27.78% YoY, though the company remains unprofitable with a net loss of $62.43 million. Revenue and gross margin remain at zero, reflecting the pre-revenue stage of the company.
Analysts are highly bullish on MLTX, with multiple upgrades and increased price targets. Oppenheimer raised its target to $35, Clear Street to $45, and H.C. Wainwright to $32, all citing the strong clinical data and regulatory clarity as key drivers for future growth.
